Nascent Biotech Inc. (NBIO) financial statements (2020 and earlier)

Company profile

Business Address 6330 NANCY RIDGE DR.
SAN DIEGO, CA 92121
State of Incorp. NV
Fiscal Year End March 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2019
TTM
3/31/2019
3/31/2018
3/31/2017
3/31/2016
3/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2131117130573108
Cash and cash equivalents2131117130573108
Receivables38  6060 
Prepaid expense     2
Other undisclosed current assets(38)  (60)(60) 
Total current assets:2131117130573110
Noncurrent Assets
Other undisclosed noncurrent assets   770828828
Total noncurrent assets:   770828828
TOTAL ASSETS:21311179001,401938
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:840526203(19)(19)1,281
Accounts payable 5262031522,3391,276
Accrued liabilities6    5
Other undisclosed accounts payable and accrued liabilities834  (171)(2,358) 
Debt   (60)  
Derivative instruments and hedges, liabilities   046
Due to related parties11588   1
Other undisclosed current liabilities   2452,9851,797
Total current liabilities:9546142031662,9703,085
Noncurrent Liabilities
Other undisclosed noncurrent liabilities   (19)(19)60
Total noncurrent liabilities:   (19)(19)60
Other undisclosed liabilities   1919 
Total liabilities:9546142031662,9703,145
Stockholders' equity
Stockholders' equity attributable to parent(953)(482)(86)734(1,569)(2,207)
Preferred stock0     
Common stock363328232218
Additional paid in capital12,82112,31911,3509,9548,7904,007
Accumulated deficit(13,809)(12,833)(11,465)(9,243)(10,380)(6,231)
Total stockholders' equity:(953)(482)(86)734(1,569)(2,207)
TOTAL LIABILITIES AND EQUITY:21311179001,401938

Income statement (P&L) ($ in thousands)

12/31/2019
TTM
3/31/2019
3/31/2018
3/31/2017
3/31/2016
3/31/2015
Revenues   3,000  
Cost of revenue
(Cost of Goods and Services Sold)
  (2,000)(333)  
Gross profit:  (2,000)2,667  
Operating expenses(1,123)(1,369)(2,222)(1,573)(4,718)(2,123)
Other undisclosed operating income (loss)(181) 2,000333847 
Operating income (loss):(1,304)(1,369)(2,222)1,427(3,871)(2,123)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(6)00(50)(278)(29)
Interest and debt expense6  145(1,574)(24)
Income (loss) from continuing operations before equity method investments, income taxes:(1,304)(1,369)(2,221)1,522(5,722)(2,176)
Other undisclosed loss from continuing operations before income taxes   (145)  
Income (loss) from continuing operations before income taxes:(1,304)(1,369)(2,221)1,377(5,722)(2,176)
Income tax expense   (240)  
Income (loss) before gain (loss) on sale of properties:(1,304)(1,369)(2,221)1,137(5,722)(2,176)
Other undisclosed net loss(6)     
Net income (loss):(1,310)(1,369)(2,221)1,137(5,722)(2,176)
Other undisclosed net income (loss) attributable to parent0 (0) 1,57424
Net income (loss) available to common stockholders, diluted:(1,310)(1,369)(2,222)1,137(4,149)(2,152)

Comprehensive Income ($ in thousands)

12/31/2019
TTM
3/31/2019
3/31/2018
3/31/2017
3/31/2016
3/31/2015
Net income (loss):(1,310)(1,369)(2,221)1,137(5,722)(2,176)
Comprehensive income (loss), net of tax, attributable to parent:(1,310)(1,369)(2,221)1,137(5,722)(2,176)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: